Effective at the close of business, Friday, Aug. 1, 2025, the 11 per cent unsecured convertible debentures (listed under the symbol LSL.DB) of LSL Pharma Group Inc. will be delisted from the TSX Venture Exchange due to the early redemption of the convertible debentures.

Pursuant to the company's news release of July 2, 2025, the convertible debentures will be redeemed on Aug. 4, 2025, in accordance with the terms of the trust indenture dated Nov. 1, 2023, between the company and TSX Trust Company.

The following mandatory settlement rules will apply.

Trade dates on Aug. 1, 2025, will settle on Aug. 1, 2025.

On Aug. 1, 2025, trading in the convertible debentures shall be cash same-day settlement.

The company's common shares (listed under the symbol LSL) will continue to trade on the TSX Venture Exchange.

For more information, refer to the company's news release dated July 2, 2025.